Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Novartis AG

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BASEL, NOVEMBER 4, 2025  NOVARTIS WILL PRESENT NEW DATA FROM 33 ABSTRACTS ACROSS ITS CARDIOVASCULAR, RENAL, AND METABOLIC (CRM) DISEASE PORTFOLIO AT THE UPCOMING AMERICAN SOCIETY OF NEPHROLOGY (ASN) KIDNEY WEEK 2025 IN HOUSTON, TEXAS AND AMERICAN HEART ASSOCIATION'S (AHA) SCIENTIFIC SESSIONS 2025 IN NEW ORLEANS, LOUISIANA, ADVANCING SCIENTIFIC INSIGHT INTO THESE CRITICAL DISEASE AREAS. NOVARTIS WILL PRESENT A BROAD RANGE OF DATA AT ASN AND AHA DEMONSTRATING INNOVATION AND COMMITMENT TO ADVANCING THERAPIES THAT ADDRESS ROOT CAUSES OF HEART AND KIDNEY CONDITIONS, SAID RUCHIRA GLASER, M.D., GLOBAL HEAD, CARDIOVASCULAR, RENAL AND METABOLIC DEVELOPMENT UNIT, NOVARTIS. "STUDIES ON BOTH OUR APPROVED AND INVESTIGATIONAL THERAPIES IN THESE CLOSELY CONNECTED THERAPEUTIC AREAS REFLECT OUR LONGSTANDING DEDICATION TO DELIVER MEANINGFUL SOLUTIONS FOR PATIENTS LIVING WITH SOME OF THE RAREST TO MOST PREVALENT CRM DISEASES WORLDWIDE. KEY HIGHLIGHTS OF DATA ACCEPTED BY ASN INCLUDE:

NEW NOVARTIS DATA AT ASN KIDNEY WEEK AND AHA SCIENTIFIC SESSIONS DEMONSTRATE MOMENTUM OF BROAD CRM PORTFOLIO AND PIPELINE

NASHVILLE, TENN.--(BUSINESS WIRE)--THE SCHOOL OF GLOBAL HEALTH AT MEHARRY MEDICAL COLLEGE, IN PARTNERSHIP WITH NOVARTIS, TODAY ANNOUNCED THE LAUNCH OF HEALTH ASSESSMENTS AND RAPID TRANSFORMATION (HEART), A FIVE-YEAR INITIATIVE THAT AIMS TO IMPROVE HEART HEALTH IN THREE US CITIES THROUGH POPULATION HEALTH APPROACHES ADDRESSING CLINICAL AND NON-CLINICAL DETERMINANTS OF HEALTH. GUIDED BY COMMUNITY VOICES AND POWERED BY RESEARCH, POLICY, AND TECHNOLOGY, HEART SEEKS TO REDUCE CARDIOVASCULAR HEALTH D.

MEHARRY AND NOVARTIS PARTNER ON HEART INITIATIVE FOR HEALTHIER COMMUNITIES

BASEL, OCTOBER 29, 2025  NOVARTIS TODAY PRESENTED NEW IANALUMAB DATA IN SJGREN'S DISEASE, THE SECOND MOST PREVALENT RHEUMATIC AUTOIMMUNE DISEASE2, AT A LATE-BREAKER PRESENTATION DURING THE AMERICAN COLLEGE OF RHEUMATOLOGY CONVERGENCE CONGRESS1.

NOVARTIS IANALUMAB FIRST DRUG TO REDUCE DISEASE ACTIVITY AND PATIENT BURDEN IN SJGREN'S DISEASE PHASE III TRIALS

BASEL, OCTOBER 28, 2025 - NOVARTIS TODAY ANNOUNCED THAT IT HAS SUCCESSFULLY COMPLETED ITS ACQUISITION OF TOURMALINE BIO, INC. (TOURMALINE). WITH THE COMPLETION OF THE ACQUISITION, SHARES OF COMMON STOCK, PAR VALUE $0.0001 PER SHARE (THE SHARES), OF TOURMALINE, HAVE CEASED TRADING ON THE NASDAQ STOCK MARKET LLC AND TOURMALINE IS NOW AN INDIRECT WHOLLY OWNED SUBSIDIARY OF NOVARTIS.

NOVARTIS COMPLETES ACQUISITION OF TOURMALINE BIO

BASEL, OCTOBER 28 2025- NOVARTIS TODAY ANNOUNCED THAT ITS PREVIOUSLY ANNOUNCED TENDER OFFER (THE OFFER) BY TORINO MERGER SUB INC., A DELAWARE CORPORATION AND AN INDIRECT WHOLLY OWNED SUBSIDIARY OF NOVARTIS (PURCHASER), TO ACQUIRE ALL OF THE OUTSTANDING SHARES OF COMMON STOCK, PAR VALUE $0.0001 PER SHARE (THE SHARES), OF TOURMALINE BIO, INC., A DELAWARE CORPORATION (TOURMALINE), AT A PRICE OF $48.00 PER SHARE, IN CASH, WITHOUT INTEREST AND SUBJECT TO ANY APPLICABLE WITHHOLDING, EXPIRED AT ONE MINUTE FOLLOWING 11:59 P.M., EASTERN TIME, ON OCTOBER 27, 2025 (THE EXPIRATION DATE).

NOVARTIS ANNOUNCES EXPIRATION OF TOURMALINE BIO TENDER OFFER

Q3 NET SALES GREW +7% (CC1, +8% USD) AND CORE OPERATING INCOME1 GREW +7% (CC, +6% USD). SALES GROWTH WAS DRIVEN BY CONTINUED STRONG EXECUTION ON PRIORITY BRANDS INCLUDING KISQALI (+68% CC), KESIMPTA (+44% CC), PLUVICTO (+45% CC) AND SCEMBLIX (+95% CC).

NOVARTIS DELIVERS SOLID SALES AND CORE OPERATING INCOME GROWTH WITH STRONG PIPELINE PROGRESS IN Q3; REAFFIRMS FY 2025 GUIDANCE

NOVARTIS TO ACQUIRE AVIDITY FOR USD 72.00 PER SHARE IN CASH FOR TOTAL EQUITY VALUE OF APPROXIMATELY USD 12.0 BILLION AVIDITY EXPECTS TO SEPARATE ITS EARLY-STAGE PRECISION CARDIOLOGY PROGRAMS INTO A NEW COMPANY ("SPINCO") CLOSING EXPECTED IN 1H2026 SUBJECT TO COMPLETION OF THE SEPARATION OF SPINCO FROM AVIDITY AND OTHER CUSTOMARY CLOSING CONDITIONS SAN DIEGO , OCT. 26, 2025 /PRNEWSWIRE/ -- AVIDITY BIOSCIENCES, INC. ("AVIDITY") (NASDAQ: RNA), A BIOPHARMACEUTICAL COMPANY COMMITTED TO DELIVERING A NEW CLASS OF RNA THERAPEUTICS CALLED ANTIBODY OLIGONUCLEOTIDE CONJUGATES ("AOCS") TO PROFOUNDLY IMPROVE PEOPLE'S LIVES, TODAY ANNOUNCED THAT IT HAS ENTERED INTO A DEFINITIVE MERGER AGREEMENT WITH NOVARTIS AG ("NOVARTIS") WHICH HAS BEEN UNANIMOUSLY APPROVED BY THE BOARDS OF DIRECTORS OF BOTH COMPANIES.THE ACQUISITION WILL FOLLOW THE SEPARATION OF AVIDITY'S EARLY-STAGE PRECISION CARDIOLOGY PROGRAMS INTO SPINCO, WHICH IS EXPECTED TO BE A PUBLICLY TRADED COMPANY.

AVIDITY BIOSCIENCES ENTERS INTO AGREEMENT TO BE ACQUIRED BY NOVARTIS AG

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR TRANSACTION STRENGTHENS NEUROSCIENCE FRANCHISE FOR NOVARTIS WITH THREE LATE-STAGE PROGRAMS THAT ADDRESS GENETIC NEUROMUSCULAR DISEASES ADVANCES THE NOVARTIS XRNA STRATEGY BY ADDING A SCIENTIFICALLY ROBUST, MUSCLE-DIRECTED, ANTIBODY OLIGONUCLEOTIDE CONJUGATES (AOCS) PLATFORM AND FIRST-IN-DISEASE PIPELINE EXPECTED TO UNLOCK MULTI-BILLION-DOLLAR OPPORTUNITIES WITH PLANNED PRODUCT LAUNCHES BEFORE 2030 RAISES EXPECTED 2024-2029 SALES CAGR FOR NOVARTIS FROM +5% TO +6%, AND BOLSTERS MID-SINGLE DIGIT LONG-TERM GROWTH AS PART OF THE AGREEMENT, AVIDITY WILL SEPARATE ITS EARLY-STAGE PRECISION CARDIOLOGY PROGRAMS INTO A NEW COMPANY (SPINCO) PRIOR TO CLOSING CONSIDERATION TOTALS USD 12BN IN CASH; CLOSING EXPECTED IN H1 2026 SUBJECT TO COMPLETION OF THE SEPARATION OF SPINCO FROM AVIDITY AND OTHER CUSTOMARY CLOSING CONDITIONS BASEL, OCTOBER 26, 2025  NOVARTIS TODAY ANNOUNCED THAT IT HAS ENTERED INTO AN AGREEMENT TO ACQUIRE AVIDITY BIOSCIENCES, INC. (NASDAQ: RNA), A SAN DIEGO-BASED, BIOPHARMACEUTICAL COMPANY FOCUSED ON A NEW CLASS OF THERAPEUTICS ENABLING RNA DELIVERY TO MUSCLE.

NOVARTIS AGREES TO ACQUIRE AVIDITY BIOSCIENCES, AN INNOVATOR IN RNA THERAPEUTICS, STRENGTHENING ITS LATE-STAGE NEUROSCIENCE PIPELINE

BASEL, OCTOBER 25, 2025  NOVARTIS ANNOUNCED TODAY PLANS TO PRESENT DATA FROM 27 COMPANY- OR INVESTIGATOR-SPONSORED ABSTRACTS ACROSS ITS IMMUNOLOGY PORTFOLIO AND PIPELINE AT THE 2025 AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) CONVERGENCE. DATA TO BE PRESENTED INCLUDE LATE-BREAKING PIVOTAL PHASE III RESULTS FROM THE REPLICATE NEPTUNUS-1 AND NEPTUNUS-2 TRIALS EVALUATING IANALUMAB IN SJGREN'S DISEASE1. NEW BIOMARKER DATA FROM AN ONGOING PHASE 1/2 STUDY OF RAPCABTAGENE AUTOLEUCEL IN SEVERE REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS WILL ALSO BE PRESENTED, ALONG WITH COSENTYX DATA IN MULTIPLE RHEUMATOLOGY INDICATIONS2,3. OUR DATA AT THIS YEAR'S ACR DEMONSTRATE THAT NOVARTIS IS AT THE FOREFRONT OF SCIENTIFIC INNOVATION AND IS DEVELOPING MEDICINES FOR SOME OF THE MOST CHALLENGING AUTOIMMUNE DISEASES, SUCH AS SJGREN'S, SAID ANGELIKA JAHREIS, GLOBAL HEAD, DEVELOPMENT, IMMUNOLOGY, NOVARTIS. AUTOIMMUNE DISEASES ARE OFTEN DEVASTATING AND LIFE-LIMITING. WE ARE COMMITTED TO DEVELOPING NEW THERAPIES WITH THE POTENTIAL TO TRANSFORM THE STANDARD OF CARE FOR THE MILLIONS WHO CONTINUE TO SUFFER FROM RHEUMATIC DISEASES. IANALUMAB IS AN INVESTIGATIONAL MEDICINE THAT HAS THE POTENTIAL TO BECOME THE FIRST TARGETED THERAPY FOR SJGREN'S DISEASE, AN AREA OF HIGH UNMET NEED WITH NO FDA-APPROVED TREATMENTS4,5. SJGREN'S DISEASE AFFECTS MILLIONS OF PEOPLE GLOBALLY AND IS THE SECOND MOST PREVALENT RHEUMATIC DISEASE6. ADDITIONAL PRESENTATIONS INCLUDE DATA FOR RAPCABTAGENE AUTOLEUCEL, A NOVEL ONE-TIME INVESTIGATIONAL CAR-T CELL THERAPY BEING EVALUATED ACROSS SEVERAL REFRACTORY AUTOIMMUNE DISEASE FOR ITS POTENTIAL TO INDUCE AN IMMUNE RESET7 -9. FURTHER PRESENTATIONS WILL FEATURE REAL-WORLD DATA ON COSENTYX (SECUKINUMAB) IN PSORIATIC ARTHRITIS, AND NEW INSIGHTS INTO THE DUAL MODE OF ACTION OF IANALUMAB. INVESTOR CALL ON NOVARTIS IMMUNOLOGY PIPELINE FOLLOWING THE CONCLUSION OF ACR, NOVARTIS WILL HOST A CONFERENCE CALL FOR INVESTORS TO PROVIDE UPDATES ON THE COMPANY'S IMMUNOLOGY PIPELINE ON THURSDAY, OCTOBER 3

NOVARTIS SHOWCASES SIGNIFICANT IMMUNOLOGY ADVANCEMENTS IN ACR CONGRESS WITH NEW DATA IN COMPLEX AUTOIMMUNE DISEASES

BASEL, OCTOBER 22, 2025 NOVARTIS TODAY ANNOUNCED THAT COSENTYX (SECUKINUMAB) MET THE PRIMARY ENDPOINT AND ALL SECONDARY ENDPOINTS IN THE PHASE III REPLENISH TRIAL1. COSENTYX DEMONSTRATED STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL SUSTAINED REMISSION VS PLACEBO AT WEEK 52 IN ADULTS WITH POLYMYALGIA RHEUMATICA (PMR)1. DATA WILL BE PRESENTED AT AN UPCOMING MEDICAL CONGRESS AND SUBMITTED TO HEALTH AUTHORITIES IN THE FIRST HALF OF 2026. POLYMYALGIA RHEUMATICA IS AN INFLAMMATORY RHEUMATIC DISEASE CHARACTERIZED BY BILATERAL PAIN OF THE NECK, SHOULDERS, OR HIPS, MORNING STIFFNESS, AND FATIGUE. IT TENDS TO FLARE AND SIGNIFICANTLY IMPACT PATIENTS' QUALITY OF LIFE, SAID ANGELIKA JAHREIS, GLOBAL HEAD, IMMUNOLOGY DEVELOPMENT, NOVARTIS. THESE RESULTS HIGHLIGHT THE POTENTIAL OF COSENTYX TO HELP PATIENTS ACHIEVE AND SUSTAIN DISEASE REMISSION AND REDUCE CORTICOSTEROIDS, WHICH CAN LEAD TO SIGNIFICANT SIDE EFFECTS IN THIS TYPICALLY ELDERLY PATIENT POPULATION. TODAY'S RESULTS REPRESENT ANOTHER BREAKTHROUGH IN TRANSFORMING CARE IN RHEUMATOLOGY. A KEY SECONDARY ENDPOINT OF THE REPLENISH TRIAL WAS ADJUSTED ANNUAL CUMULATIVE STEROID DOSE THROUGH WEEK 52. OTHER SECONDARY MEASURES INCLUDED COMPLETE SUSTAINED REMISSION AT WEEK 52, AND TIME UNTIL PATIENTS NEEDED ADDITIONAL TREATMENT3. ABOUT REPLENISH TRIAL THE REPLENISH TRIAL (NCT05767034) IS A GLOBAL PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY CONDUCTED ACROSS 27 COUNTRIES, EVALUATING THE EFFICACY AND SAFETY OF COSENTYX IN PATIENTS WITH POLYMYALGIA RHEUMATICA (PMR). PATIENTS WERE RANDOMIZED INTO THREE TREATMENT ARMS: COSENTYX 300MG, COSENTYX 150MG, OR PLACEBO, ALL IN COMBINATION WITH A 24-WEEK STEROID TAPER REGIMEN. THE PRIMARY ENDPOINT OF THE TRIAL IS TO ASSESS WHETHER SECUKINUMAB 300MG SC. PLUS A 24-WEEK STEROID TAPER IS SUPERIOR TO PLACEBO PLUS A 24-WEEK STEROID TAPER IN ACHIEVING SUSTAINED REMISSION AT WEEK 52. KEY SECONDARY ENDPOINTS INCLUDE THE PROPORTION OF PATIENTS ACHIEVING COMP

NOVARTIS COSENTYX MEETS PRIMARY AND ALL SECONDARY ENDPOINTS IN PHASE III TRIAL IN PATIENTS WITH POLYMYALGIA RHEUMATICA (PMR)

BASEL, OCTOBER 22, 2025- NOVARTIS TODAY ANNOUNCED THE EXPIRATION OF THE WAITING PERIOD UNDER THE HART-SCOTT-RODINO ANTITRUST IMPROVEMENTS ACT OF 1976, AS AMENDED (THE HSR ACT), IN CONNECTION WITH NOVARTIS' PREVIOUSLY ANNOUNCED TENDER OFFER TO ACQUIRE ALL OF THE OUTSTANDING SHARES OF COMMON STOCK, PAR VALUE $0.0001 PER SHARE (THE SHARES), OF TOURMALINE BIO, INC., A DELAWARE CORPORATION (TOURMALINE), AT A PRICE OF $48.00 PER SHARE, IN CASH, WITHOUT INTEREST AND SUBJECT TO ANY APPLICABLE WITHHOLDING. THE EXPIRATION OF THE HSR ACT WAITING PERIOD OCCURRED AT 11:59 P.M., EASTERN TIME, ON OCTOBER 21, 2025.EXPIRATION OF THE WAITING PERIOD UNDER THE HSR ACT SATISFIES ONE OF THE CONDITIONS NECESSARY FOR THE CONSUMMATION OF THE TRANSACTIONS CONTEMPLATED BY THE AGREEMENT AND PLAN OF MERGER, DATED AS OF SEPTEMBER8, 2025 (THE MERGER AGREEMENT), AMONG NOVARTIS, TORINO MERGER SUB INC., A DELAWARE CORPORATION AND AN INDIRECT WHOLLY OWNED SUBSIDIARY OF NOVARTIS (PURCHASER), AND TOURMALINE, INCLUDING THE TENDER OFFER AND THE SUBSEQUENT MERGER, WHICH REMAIN SUBJECT TO THE CONDITION THAT THERE BE VALIDLY TENDERED AND NOT VALIDLY WITHDRAWN IN ACCORDANCE WITH THE TERMS OF THE OFFER, IMMEDIATELY PRIOR TO THE EXPIRATION DATE (AS DEFINED BELOW) A NUMBER OF SHARES THAT, TOGETHER WITH ANY SHARES THEN OWNED BY NOVARTIS OR ANY OF ITS DIRECT OR INDIRECT WHOLLY OWNED SUBSIDIARIES, REPRESENTS AT LEAST A MAJORITY OF SHARES OUTSTANDING AT THE TIME OF EXPIRATION OF THE OFFER. THE OFFER WILL EXPIRE AT ONE MINUTE FOLLOWING 11:59 P.M., EASTERN TIME, ON OCTOBER 27, 2025, UNLESS THE OFFER IS OTHERWISE EXTENDED (SUCH DATE OR SUBSEQUENT DATE TO WHICH THE EXPIRATION OF THE OFFER IS EXTENDED IN ACCORDANCE WITH THE TERMS OF THE MERGER AGREEMENT, THE EXPIRATION DATE) OR EARLIER TERMINATED IN ACCORDANCE WITH THE MERGER AGREEMENT.

NOVARTIS ANNOUNCES EXPIRATION OF HART-SCOTT-RODINO WAITING PERIOD OF TOURMALINE BIO TENDER OFFER

BASEL, OCTOBER 19, 2025  NOVARTIS TODAY PRESENTS NEW PLUVICTO (LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN) DATA FROM THE PHASE III PSMADDITION TRIAL IN A PRESIDENTIAL SYMPOSIUM AT THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) CONGRESS 2025. PLUVICTO PLUS STANDARD OF CARE (SOC) (ANDROGEN RECEPTOR PATHWAY INHIBITOR [ARPI] + ANDROGEN DEPRIVATION THERAPY [ADT]) DEMONSTRATED A STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN RADIOGRAPHIC PROGRESSION-FREE SURVIVAL (RPFS), REDUCING THE RISK OF RADIOGRAPHIC PROGRESSION OR DEATH BY 28% (HR 0.72; 95% CI: 0.58, 0.90) VERSUS SOC ALONE IN PATIENTS WITH PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)+ METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)1. RESULTS ALSO SHOW AN EARLY POSITIVE TREND IN OVERALL SURVIVAL (OS) IN PATIENTS TREATED WITH PLUVICTO PLUS SOC (HR 0.84; 95% CI: 0.63, 1.13); FOLLOW-UP WILL CONTINUE UNTIL DATA ARE MATURE1. MORE PATIENTS ACHIEVED A COMPLETE RESPONSE VERSUS SOC ALONE (57.1% VS. 42.3%) AND THE OVERALL RESPONSE RATE (ORR) WAS NUMERICALLY HIGHER IN THE PLUVICTO PLUS SOC ARM (85.3% VS. 80.8%)1. PLUVICTO DELAYED TIME TO PROGRESSION TO METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) (HR 0.70; 95% CI: 0.58, 0.84)1. THE RPFS BENEFIT WAS CONSISTENT ACROSS PRE-SPECIFIED SUBGROUPS1. IN METASTATIC PROSTATE CANCER, CHOOSING THE MOST EFFICACIOUS TREATMENT EARLY IS CRUCIAL, EVEN AT INITIAL DIAGNOSIS, SAID SCOTT T. TAGAWA, MD, A PROFESSOR OF MEDICINE AT WEILL CORNELL MEDICINE AND A MEDICAL ONCOLOGIST AT NEWYORK-PRESBYTERIAN/WEILL CORNELL MEDICAL CENTER. THESE FINDINGS SUGGEST THAT COMBINING177LU-PSMA-617 WITH STANDARD OF CARE HORMONAL THERAPY OFFERS PATIENTS MORE TIME WITHOUT DISEASE PROGRESSION, A SAFETY PROFILE WITH ADVERSE EVENTS THAT ARE MOST OFTEN LOW GRADE AND MANAGED WITH SUPPORTIVE CARE, AND AN ENCOURAGING TREND IN OVERALL SURVIVAL. THESE RESULTS REINFORCE THE POTENTIAL FOR PLUVICTO, A RADIOLIGAND THERAPY THAT DELIVERS TREATMENT DIRECTLY TO TARGET CELLS, TO CHANGE HOW WE TREAT METASTATI

PSMADDITION DATA SHOW NOVARTIS PLUVICTO DELAYS PROGRESSION TO END-STAGE PROSTATE CANCER

BASEL, OCTOBER 17, 2025  NOVARTIS TODAY ANNOUNCED RESULTS FROM THE FIVE-YEAR ANALYSIS OF THE PIVOTAL PHASE III NATALEE TRIAL OF KISQALI (RIBOCICLIB) THAT DEMONSTRATED A SUSTAINED BENEFIT AT A MEDIAN OF TWO YEARS AFTER A THREE-YEAR TREATMENT WITH KISQALI (MEDIAN FOLLOW-UP: 58.4 MONTHS). RESULTS SHOWED A 28.4% REDUCTION IN RISK OF RECURRENCE (HR=0.716; 95% CI 0.618-0.829; NOMINAL P-VALUE

NOVARTIS KISQALI 5-YEAR NATALEE DATA DEMONSTRATE 28% REDUCTION IN RISK OF RECURRENCE IN THE BROADEST EARLY BREAST CANCER PATIENT POPULATION

BASEL, OCTOBER 17, 2025  NOVARTIS ANNOUNCED TODAY THAT THE COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) OF THE EUROPEAN MEDICINES AGENCY (EMA) HAS ADOPTED A POSITIVE OPINION AND RECOMMENDED GRANTING MARKETING AUTHORIZATION FOR SCEMBLIX  (ASCIMINIB) FOR THE TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (PH+ CML-CP) IN ALL LINES OF TREATMENT. FOR PEOPLE LIVING WITH CML, LONG-TERM THERAPY CAN BE PHYSICALLY AND EMOTIONALLY DEMANDING, AND MANY FACE CHALLENGES IN REACHING TREATMENT MILESTONES WITHOUT COMPROMISING QUALITY OF LIFE, SAIDDAVIDFITZGERALD, MEMBER OF THE CML ADVOCATES NETWORK. THE AVAILABILITY OF MORE TREATMENT OPTIONS EARLIER IN THE CARE PATHWAY IS A WELCOME DEVELOPMENT THAT BRINGS FORWARD ADDITIONAL POSSIBILITIES FOR PATIENTS AND THEIR HEALTHCARE TEAMS TO CHOOSE APPROACHES THAT BEST SUPPORT BOTH CLINICAL GOALS AND PATIENT WELL-BEING. THE POSITIVE CHMP OPINION IS BASED ON DATA FROM THE PHASE III ASC4FIRST TRIAL, WHICH COMPARED SCEMBLIX WITH INVESTIGATORS' CHOICE OF TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN PATIENTS WITH NEWLY DIAGNOSED PH+ CML-CP1 ,2. IN THE TRIAL, SCEMBLIX DEMONSTRATED SUPERIOR MAJOR MOLECULAR RESPONSE (MMR) RATES WHEN COMPARED AGAINST ALL TKIS (IMATINIB, NILOTINIB, DASATINIB AND BOSUTINIB) AND ALSO WHEN COMPARED AGAINST IMATINIB ALONE1 ,2. PATIENTS TREATED WITH SCEMBLIX ALSO REQUIRED FEWER DOSE REDUCTIONS AND EXPERIENCED HALF THE RATE OF ADVERSE EVENTS LEADING TO DISCONTINUATION1 ,2. "TO GIVE PATIENTS NEWLY DIAGNOSED WITH CML THE BEST CHANCE TO REACH KEY EFFICACY MILESTONES WHILE MAINTAINING QUALITY OF LIFE, IT IS CRITICAL TO INTERVENE EARLY WITH A MORE SELECTIVE TREATMENT THAT COMBINES SUPERIOR EFFICACY WITH TOLERABILITY," SAID PROFESSOR ANDREAS HOCHHAUS, HEAD OF THE DEPARTMENT OF HEMATOLOGY AND MEDICAL ONCOLOGY AT JENA UNIVERSITY HOSPITAL, GERMANY. "IF APPROVED, SCEMBLIX COULD PROVIDE PATIENTS WITH A WELL-TOLERATED OPTION THAT MAY DELIVER FASTER, DEEPER AND LONGER-LAS

NOVARTIS SCEMBLIX RECEIVES POSITIVE CHMP OPINION FOR THE TREATMENT OF ADULTS WITH NEWLY DIAGNOSED CML

BASEL, OCTOBER 16, 2025  NOVARTIS TODAY ANNOUNCED POSITIVE FINAL RESULTS FROM APPLAUSE-IGAN, A PHASE III STUDY EVALUATING FABHALTA (IPTACOPAN) IN ADULTS LIVING WITH IGA NEPHROPATHY (IGAN). FABHALTA, AN ORAL ALTERNATIVE COMPLEMENT PATHWAY INHIBITOR, DEMONSTRATED STATISTICALLY SIGNIFICANT, CLINICALLY MEANINGFUL SUPERIORITY COMPARED TO PLACEBO IN SLOWING IGAN PROGRESSION MEASURED BY ANNUALIZED TOTAL SLOPE OF ESTIMATED GLOMERULAR FILTRATION RATE (EGFR) DECLINE OVER TWO YEARS1.

NOVARTIS FABHALTA (IPTACOPAN) MEETS PHASE III PRIMARY ENDPOINT, SLOWS KIDNEY FUNCTION DECLINE IN PATIENTS WITH IGA NEPHROPATHY (IGAN)

RHAPSIDO HELPS TO INHIBIT RELEASE OF HISTAMINE AND PROINFLAMMATORY MEDIATORS BY TARGETING BTK, OFFERING UNIQUE APPROACH TO CSU TREATMENT 1 WELL-CONTROLLED DISEASEOBSERVED AS FAST AS TWO WEEKS, WITH DEMONSTRATED SAFETY PROFILE THAT REQUIRES NO LAB MONITORING 1 1.7 MILLION PEOPLE IN US LIVE WITH CSU; MORE THAN HALF REMAIN SYMPTOMATIC DESPITE INCREASING DOSES OF ANTIHISTAMINES 2,3 REMIBRUTINIB ALSO IN CLINICAL DEVELOPMENT FOR CHRONIC INDUCIBLE URTICARIA, FOOD ALLERGY, AND HIDRADENITIS SUPPURATIVA, EXPANDING NOVARTIS IMMUNOLOGY PORTFOLIO EAST HANOVER, N.J. , SEPT. 30, 2025 /PRNEWSWIRE/ -- NOVARTIS ANNOUNCED TODAY THAT RHAPSIDO (REMIBRUTINIB) RECEIVED US FOOD AND DRUG ADMINISTRATION (FDA) APPROVAL AS AN ORAL TREATMENT FOR ADULT PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA (CSU) WHO REMAIN SYMPTOMATIC DESPITE H1 ANTIHISTAMINE TREATMENT.

NOVARTIS RECEIVES FDA APPROVAL FOR RHAPSIDO (REMIBRUTINIB), THE ONLY ORAL, TARGETED BTKI TREATMENT FOR CHRONIC SPONTANEOUS URTICARIA (CSU)

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR RHAPSIDO HELPS TO INHIBIT RELEASE OF HISTAMINE AND PROINFLAMMATORY MEDIATORS BY TARGETING BTK, OFFERING UNIQUE APPROACH TO CSU TREATMENT 1 WELL-CONTROLLED DISEASE OBSERVED AS FAST AS TWO WEEKS, WITH DEMONSTRATED SAFETY PROFILE THAT REQUIRES NO LAB MONITORING 1 1.7 MILLION PEOPLE IN US LIVE WITH CSU; MORE THAN HALF REMAIN SYMPTOMATIC DESPITE INCREASING DOSES OF ANTIHISTAMINES 2,3 REMIBRUTINIB ALSO IN CLINICAL DEVELOPMENT FOR CHRONIC INDUCIBLE URTICARIA, FOOD ALLERGY, AND HIDRADENITIS SUPPURATIVA, EXPANDING NOVARTIS IMMUNOLOGY PORTFOLIO BASEL, SEPTEMBER 30, 2025  NOVARTIS ANNOUNCED TODAY THAT RHAPSIDO (REMIBRUTINIB) RECEIVED US FOOD AND DRUG ADMINISTRATION (FDA) APPROVAL AS AN ORAL TREATMENT FOR ADULT PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA (CSU) WHO REMAIN SYMPTOMATIC DESPITE H1 ANTIHISTAMINE TREATMENT.

BASEL, SEPTEMBER 29, 2025  TODAY, NOVARTIS ANNOUNCED PLANS TO LAUNCH A DIRECT-TO-PATIENT (DTP) PLATFORM IN THE US WHICH WILL COME INTO EFFECT ON NOVEMBER 1, 2025, OFFERING CASH-PAYING PATIENTS PRESCRIBED COSENTYX (SECUKINUMAB) THE OPTION TO PURCHASE IT AT A 55% DISCOUNT OFF THE LIST PRICE. COSENTYX, NOVARTIS TOP SELLING PRODUCT IN THE US, IS A BIOLOGIC THAT IS FDA-APPROVED FOR THE TREATMENT OF MULTIPLE IMMUNE-MEDIATED INFLAMMATORY DISEASES, INCLUDING PSORIASIS, HIDRADENITIS SUPPURATIVA AND PSORIATIC ARTHRITIS.IT HAS BEEN STUDIED CLINICALLY FOR MORE THAN 17 YEARS AND HAS BEEN USED TO TREAT MORE THAN 1.8 MILLION PATIENTS GLOBALLY SINCE ITS LAUNCH IN 2015.

NOVARTIS TO LAUNCH DIRECT-TO-PATIENT PLATFORM FOR COSENTYX (SECUKINUMAB) IN THE US

BASEL, SEPTEMBER 29, 2025- NOVARTIS TODAY ANNOUNCED THAT TORINO MERGER SUB INC., A DELAWARE CORPORATION AND AN INDIRECT WHOLLY OWNED SUBSIDIARY OF NOVARTIS (PURCHASER), HAS COMMENCED A TENDER OFFER TO ACQUIRE ALL OF THE OUTSTANDING SHARES OF COMMON STOCK, PAR VALUE $0.0001 PER SHARE (THE SHARES), OF TOURMALINE BIO, INC., A DELAWARE CORPORATION (TOURMALINE), AT A PRICE OF $48 PER SHARE, IN CASH, WITHOUT INTEREST AND SUBJECT TO ANY APPLICABLE WITHHOLDING. SUCH OFFER IS BEING MADE UPON THE TERMS AND SUBJECT TO THE CONDITIONS SET FORTH IN THE OFFER TO PURCHASE, DATED SEPTEMBER 29, 2025, AND THE RELATED LETTER OF TRANSMITTAL (TOGETHER, THE OFFER) AND PURSUANT TO THE TERMS OF THE PREVIOUSLY ANNOUNCED AGREEMENT AND PLAN OF MERGER, DATED AS OF SEPTEMBER 8, 2025 (THE MERGER AGREEMENT), AMONG NOVARTIS, PURCHASER AND TOURMALINE.

NOVARTIS ANNOUNCES COMMENCEMENT OF TENDER OFFER TO ACQUIRE TOURMALINE BIO

BASEL, SEPTEMBER 26, 2025  NOVARTIS WILL PRESENT NEW DATA FROM 34 ABSTRACTS ACROSS ITS ONCOLOGY PORTFOLIO AT THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) CONGRESS 2025 IN BERLIN (OCTOBER 17-21, 2025).

NOVARTIS TO SHOWCASE TRANSFORMATIVE DATA IN ADVANCED PROSTATE AND EARLY BREAST CANCER AT ESMO 2025

BASEL, SEPTEMBER 24, 2025  NOVARTIS TODAY ANNOUNCED NEW DATA FROM TWO KESIMPTA (OFATUMUMAB) STUDIES IN RELAPSING MULTIPLE SCLEROSIS (RMS) THAT WILL BE PRESENTED AT THE EUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS (ECTRIMS) 2025 ANNUAL MEETING IN BARCELONA, SPAIN, ON SEPTEMBER 2426.

NEW NOVARTIS DATA FURTHER SUPPORT BENEFITS OF KESIMPTA IN RELAPSING MS FOLLOWING SWITCH FROM ORAL DISEASE MODIFYING THERAPIES

NOVARTIS RECEIVES AN EXCLUSIVE LICENSE TO AN UNDISCLOSED DISCOVERY TARGET NOVARTIS ALSO RECEIVES OPTIONS TO LICENSE TWO PROGRAMS FROM MONTE ROSA'S GROWING PRECLINICAL IMMUNOLOGY PORTFOLIO MONTE ROSA TO RECEIVE AN UPFRONT PAYMENT OF $120 MILLION, PLUS OPTION MAINTENANCE PAYMENTS, AND IS ELIGIBLE FOR OPTION EXERCISE PAYMENTS AND DEVELOPMENT, REGULATORY, AND SALES MILESTONES, AS WELL AS TIERED ROYALTIES ON GLOBAL NET SALES EXTENDED CASH RUNWAY ENABLES MONTE ROSA TO ACCELERATE PRECLINICAL AND CLINICAL-STAGE IMMUNOLOGY & INFLAMMATION (I&I) PIPELINE BOSTON, MASS., SEPT. 15, 2025 (GLOBE NEWSWIRE) -- MONTE ROSA THERAPEUTICS, INC. (NASDAQ: GLUE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NOVEL MOLECULAR GLUE DEGRADER (MGD)-BASED MEDICINES, TODAY ANNOUNCED AN AGREEMENT TO COLLABORATE WITH NOVARTIS TO DEVELOP NOVEL DEGRADERS FOR IMMUNE-MEDIATED DISEASES.

MONTE ROSA THERAPEUTICS ANNOUNCES COLLABORATION WITH NOVARTIS FOR DEGRADERS TO TREAT IMMUNE-MEDIATED DISEASES

 NOVARTIS TO ACQUIRE TOURMALINE BIO FOR $48.00 PER SHARE IN CASH FOR A TOTAL EQUITY VALUE OF APPROXIMATELY $1.4 BILLION   TRANSACTION REFLECTS THE POTENTIAL OF TOURMALINE'S PACIBEKITUG, A LONG-ACTING, FULLY-HUMAN, ANTI-IL-6 MONOCLONAL ANTIBODY WITH BEST-IN-CLASS POTENTIAL, FOR THE TREATMENT OF CARDIOVASCULAR DISEASES   TRANSACTION IS EXPECTED TO BE COMPLETED IN THE FOURTH QUARTER OF 2025, SUBJECT TO CUSTOMARY CLOSING CONDITIONS  NEW YORK, SEPT. 09, 2025 (GLOBE NEWSWIRE) -- TOURMALINE BIO, INC. (TOURMALINE) (NASDAQ: TRML), A LATE-STAGE CLINICAL BIOTECHNOLOGY COMPANY DEVELOPING TRANSFORMATIVE MEDICINES THAT ESTABLISH NEW STANDARDS OF CARE FOR PATIENTS WITH LIFE-ALTERING INFLAMMATORY AND IMMUNE DISEASES, TODAY ANNOUNCED THAT IT HAS ENTERED INTO A MERGER AGREEMENT WITH NOVARTIS AG (NOVARTIS), PURSUANT TO WHICH NOVARTIS WILL ACQUIRE TOURMALINE FOR $48.00 PER SHARE IN CASH AT CLOSING, OR A TOTAL EQUITY VALUE OF APPROXIMATELY $1.4 BILLION.

TOURMALINE BIO ENTERS INTO AGREEMENT TO BE ACQUIRED BY NOVARTIS AG

TOURMALINE BIO IS A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING PACIBEKITUG, AN ANTI-IL-6 MAB, AS A TREATMENT OPTION FOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE PACIBEKITUG IS A PROMISING TARGETED THERAPY WITH THE POTENTIAL TO REDUCE SYSTEMIC INFLAMMATIONAN INDEPENDENT AND SIGNIFICANT DRIVER OF CARDIOVASCULAR RISKADDRESSING A CRITICAL UNMET NEED IN ASCVD TREATMENT OFFER PRICE OF USD 48 PER SHARE VALUING THE COMPANY AT APPROXIMATELY USD 1.4BN ON A FULLY DILUTED BASIS BASEL, SEPTEMBER 9, 2025  NOVARTIS TODAY ANNOUNCED THAT IT HAS ENTERED INTO AN AGREEMENT TO ACQUIRE TOURMALINE BIO, INC. (TOURMALINE) (NASDAQ: TRML), A NEW YORK-BASED, PUBLICLY TRADED CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING PACIBEKITUG, AN ANTI-IL-6 MAB, AS A TREATMENT OPTION FOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE. PACIBEKITUG COMPLEMENTS NOVARTIS' CARDIOVASCULAR STRATEGY BY TARGETING IL-6, A KEY UPSTREAM CYTOKINE THAT PROMOTES SYSTEMIC INFLAMMATION, THUS ADDRESSING A CRITICAL UNMET NEED.

NOVARTIS TO ACQUIRE TOURMALINE BIO, COMPLEMENTING CARDIOVASCULAR PIPELINE WITH PACIBEKITUG FOR THE TREATMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD)

AGREEMENT TO EXPLORE ARGO'S PHASE 2 ANGPTL3 IN A COMBINATION TRIAL IN DYSLIPIDEMIA WITH AN OPTION TO LICENSE SECOND-GENERATION MOLECULES IN THE PIPELINE LICENSE TO AN ADDITIONAL ARGO SIRNA CANDIDATE CURRENTLY IN IND-ENABLING STUDIES ARGO WILL RECEIVE AN UPFRONT PAYMENT OF $160 MILLION, AN OPTION FOR PROFIT & LOSS SPLIT ACROSS MULTIPLE GEOGRAPHIES AND POTENTIAL NEAR-TERM EQUITY; ARGO IS ALSO ELIGIBLE TO RECEIVE OPTION PAYMENT, DEVELOPMENT, SALES MILESTONES AND ROYALTIES ON COMMERCIAL SALES SHANGHAI AND BOSTON , SEPT. 3, 2025 /PRNEWSWIRE/ -- ARGO BIOPHARMACEUTICAL CO., LTD.

Novartis AG

NVS

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Novartis AG

NVS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

NVS